ACM
ADXN

ADAR1 Capital Management’s Addex Therapeutics ADXN Stock Holding History

ADAR1 Capital Management’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$9.77K – 218
2024
Q3 		$9.77K Buy
1,000
+100
+11% +$891 ﹤0.01% 255
2024
Q2 		$7.4K Buy
900
+510
+131% +$6.28K ﹤0.01% 236
2024
Q1 		$4.99K Buy
+390
New +$3.84K ﹤0.01% 240

Other funds holding ADXN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

ADAR1 Capital Management's ADXN Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Addex Therapeutics (ADXN) in Q4 2024, closing a stake of 1,000 shares — an estimated $9.77K sold.

ADAR1 Capital Management first reported a position in ADXN in Q1 2024 and held it in 3 quarters. The position peaked at $9.77K in Q3 2024. 5 funds tracked by Wall St. Rank hold ADXN as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Addex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 1,000 Addex Therapeutics shares in Q4 2024, an estimated $9.77K.
  • ADAR1 Capital Management first reported a position in Addex Therapeutics in Q1 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Addex Therapeutics position peaked at $9.77K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.